# An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer

> **NCT07667751** · PHASE2 · RECRUITING · sponsor: **Bai-Rong Xia** · enrollment: 35 (estimated)

## Conditions studied

- Ovary Cancer

## Interventions

- **DRUG:** Sunitinib、Olaparib、Tolilizumab

## Key facts

- **NCT ID:** NCT07667751
- **Lead sponsor:** Bai-Rong Xia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667751, "An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*